199 related articles for article (PubMed ID: 36534392)
1. Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis.
Tur C; Carbonell-Mirabent P; Cobo-Calvo Á; Otero-Romero S; Arrambide G; Midaglia L; Castilló J; Vidal-Jordana Á; Rodríguez-Acevedo B; Zabalza A; Galán I; Nos C; Salerno A; Auger C; Pareto D; Comabella M; Río J; Sastre-Garriga J; Rovira À; Tintoré M; Montalban X
JAMA Neurol; 2023 Feb; 80(2):151-160. PubMed ID: 36534392
[TBL] [Abstract][Full Text] [Related]
2. Multiple Sclerosis Progression and Relapse Activity in Children.
Iaffaldano P; Portaccio E; Lucisano G; Simone M; Manni A; Guerra T; Paolicelli D; Betti M; De Meo E; Pastò L; Razzolini L; Rocca MA; Ferrè L; Brescia Morra V; Patti F; Zaffaroni M; Gasperini C; De Luca G; Ferraro D; Granella F; Pozzilli C; Romano S; Gallo P; Bergamaschi R; Coniglio MG; Lus G; Vianello M; Banfi P; Lugaresi A; Totaro R; Spitaleri D; Cocco E; Di Palma F; Maimone D; Valentino P; Torri Clerici V; Protti A; Maniscalco GT; Salemi G; Pesci I; Aguglia U; Lepore V; Filippi M; Trojano M; Amato MP;
JAMA Neurol; 2024 Jan; 81(1):50-58. PubMed ID: 38010712
[TBL] [Abstract][Full Text] [Related]
3. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
Kappos L; Wolinsky JS; Giovannoni G; Arnold DL; Wang Q; Bernasconi C; Model F; Koendgen H; Manfrini M; Belachew S; Hauser SL
JAMA Neurol; 2020 Sep; 77(9):1132-1140. PubMed ID: 32511687
[TBL] [Abstract][Full Text] [Related]
4. Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials.
Ingwersen J; Masanneck L; Pawlitzki M; Samadzadeh S; Weise M; Aktas O; Meuth SG; Albrecht P
Sci Rep; 2023 Sep; 13(1):15003. PubMed ID: 37696848
[TBL] [Abstract][Full Text] [Related]
5. Contribution of relapse-associated worsening to overall disability accrual in patients with relapsing-onset multiple sclerosis: A mediation analysis.
Chen B; Ji SQ; Shen F; Tian DS; Bu BT
Mult Scler Relat Disord; 2022 Mar; 59():103555. PubMed ID: 35093839
[TBL] [Abstract][Full Text] [Related]
6. Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.
Portaccio E; Betti M; De Meo E; Addazio I; Pastò L; Razzolini L; Totaro R; Spitaleri D; Lugaresi A; Cocco E; Onofrj M; Di Palma F; Patti F; Maimone D; Valentino P; Torri Clerici V; Protti A; Ferraro D; Lus G; Maniscalco GT; Brescia Morra V; Salemi G; Granella F; Pesci I; Bergamaschi R; Aguglia U; Vianello M; Simone M; Lepore V; Iaffaldano P; Comi G; Filippi M; Trojano M; Amato MP;
J Neurol; 2024 May; ():. PubMed ID: 38805052
[TBL] [Abstract][Full Text] [Related]
7. Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis.
Cagol A; Schaedelin S; Barakovic M; Benkert P; Todea RA; Rahmanzadeh R; Galbusera R; Lu PJ; Weigel M; Melie-Garcia L; Ruberte E; Siebenborn N; Battaglini M; Radue EW; Yaldizli Ö; Oechtering J; Sinnecker T; Lorscheider J; Fischer-Barnicol B; Müller S; Achtnichts L; Vehoff J; Disanto G; Findling O; Chan A; Salmen A; Pot C; Bridel C; Zecca C; Derfuss T; Lieb JM; Remonda L; Wagner F; Vargas MI; Du Pasquier R; Lalive PH; Pravatà E; Weber J; Cattin PC; Gobbi C; Leppert D; Kappos L; Kuhle J; Granziera C
JAMA Neurol; 2022 Jul; 79(7):682-692. PubMed ID: 35575778
[TBL] [Abstract][Full Text] [Related]
8. How patients with multiple sclerosis acquire disability.
Lublin FD; Häring DA; Ganjgahi H; Ocampo A; Hatami F; Čuklina J; Aarden P; Dahlke F; Arnold DL; Wiendl H; Chitnis T; Nichols TE; Kieseier BC; Bermel RA
Brain; 2022 Sep; 145(9):3147-3161. PubMed ID: 35104840
[TBL] [Abstract][Full Text] [Related]
9. Early onset multiple sclerosis and the effect of disease onset age on neurological disability in multiple sclerosis.
Usta NC; Boz C; Terzi M
Clin Neurol Neurosurg; 2023 Jan; 224():107528. PubMed ID: 36446265
[TBL] [Abstract][Full Text] [Related]
10. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.
Meier S; Willemse EAJ; Schaedelin S; Oechtering J; Lorscheider J; Melie-Garcia L; Cagol A; Barakovic M; Galbusera R; Subramaniam S; Barro C; Abdelhak A; Thebault S; Achtnichts L; Lalive P; Müller S; Pot C; Salmen A; Disanto G; Zecca C; D'Souza M; Orleth A; Khalil M; Buchmann A; Du Pasquier R; Yaldizli Ö; Derfuss T; Berger K; Hermesdorf M; Wiendl H; Piehl F; Battaglini M; Fischer U; Kappos L; Gobbi C; Granziera C; Bridel C; Leppert D; Maleska Maceski A; Benkert P; Kuhle J
JAMA Neurol; 2023 Mar; 80(3):287-297. PubMed ID: 36745446
[TBL] [Abstract][Full Text] [Related]
11. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
[TBL] [Abstract][Full Text] [Related]
12. Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs.
Monreal E; Fernández-Velasco JI; García-Sánchez MI; Sainz de la Maza S; Llufriu S; Álvarez-Lafuente R; Casanova B; Comabella M; Ramió-Torrentà L; Martínez-Rodríguez JE; Brieva L; Saiz A; Eichau S; Cabrera-Maqueda JM; Villarrubia N; Espiño M; Pérez-Miralles F; Montalbán X; Tintoré M; Quiroga-Varela A; Domínguez-Mozo MI; Rodríguez-Jorge F; Chico-García JL; Lourido D; Álvarez-Cermeño JC; Masjuan J; Costa-Frossard L; Villar LM
JAMA Neurol; 2023 Apr; 80(4):397-403. PubMed ID: 36848127
[TBL] [Abstract][Full Text] [Related]
13. Risk of secondary progressive multiple sclerosis after early worsening of disability.
Dzau W; Sharmin S; Patti F; Izquierdo G; Eichau S; Prat A; Girard M; Duquette P; Onofrj M; Lugaresi A; Ozakbas S; Gerlach O; Boz C; Grammond P; Terzi M; Amato MP; La Spitaleri D; Ramo-Tello C; Maimone D; Cartechini E; Buzzard K; Skibina O; van der Walt A; Butzkueven H; Iuliano G; Soysal A; Kalincik T
J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):984-991. PubMed ID: 37414538
[TBL] [Abstract][Full Text] [Related]
14. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
[TBL] [Abstract][Full Text] [Related]
15. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
16. Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS.
Cagol A; Benkert P; Melie-Garcia L; Schaedelin SA; Leber S; Tsagkas C; Barakovic M; Galbusera R; Lu PJ; Weigel M; Ruberte E; Radue EW; Yaldizli Ö; Oechtering J; Lorscheider J; D'Souza M; Fischer-Barnicol B; Müller S; Achtnichts L; Vehoff J; Disanto G; Findling O; Chan A; Salmen A; Pot C; Bridel C; Zecca C; Derfuss T; Lieb JM; Remonda L; Wagner F; Vargas MI; Du Pasquier RA; Lalive PH; Pravatà E; Weber J; Cattin PC; Absinta M; Gobbi C; Leppert D; Kappos L; Kuhle J; Granziera C
Neurology; 2024 Jan; 102(1):e207768. PubMed ID: 38165377
[TBL] [Abstract][Full Text] [Related]
17. Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study.
Portaccio E; Bellinvia A; Fonderico M; Pastò L; Razzolini L; Totaro R; Spitaleri D; Lugaresi A; Cocco E; Onofrj M; Di Palma F; Patti F; Maimone D; Valentino P; Confalonieri P; Protti A; Sola P; Lus G; Maniscalco GT; Brescia Morra V; Salemi G; Granella F; Pesci I; Bergamaschi R; Aguglia U; Vianello M; Simone M; Lepore V; Iaffaldano P; Filippi M; Trojano M; Amato MP
Brain; 2022 Aug; 145(8):2796-2805. PubMed ID: 35325059
[TBL] [Abstract][Full Text] [Related]
18. Exploring miRNAs' Based Modeling Approach for Predicting PIRA in Multiple Sclerosis: A Comprehensive Analysis.
Gosetti di Sturmeck T; Malimpensa L; Ferrazzano G; Belvisi D; Leodori G; Lembo F; Brandi R; Pascale E; Cattaneo A; Salvetti M; Conte A; D'Onofrio M; Arisi I
Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928049
[TBL] [Abstract][Full Text] [Related]
19. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis.
Baroncini D; Simone M; Iaffaldano P; Brescia Morra V; Lanzillo R; Filippi M; Romeo M; Patti F; Chisari CG; Cocco E; Fenu G; Salemi G; Ragonese P; Inglese M; Cellerino M; Margari L; Comi G; Zaffaroni M; Ghezzi A;
JAMA Neurol; 2021 Jun; 78(6):726-735. PubMed ID: 33938921
[TBL] [Abstract][Full Text] [Related]
20. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.
Muraro PA; Pasquini M; Atkins HL; Bowen JD; Farge D; Fassas A; Freedman MS; Georges GE; Gualandi F; Hamerschlak N; Havrdova E; Kimiskidis VK; Kozak T; Mancardi GL; Massacesi L; Moraes DA; Nash RA; Pavletic S; Ouyang J; Rovira M; Saiz A; Simoes B; Trnený M; Zhu L; Badoglio M; Zhong X; Sormani MP; Saccardi R;
JAMA Neurol; 2017 Apr; 74(4):459-469. PubMed ID: 28241268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
